APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oligonucleotide Drug CDMO Services

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Oligonucleotide Drug CDMO Services Market Outlook and Growth Opportunities 2026

5 June 2026205 pages

Choose your research edition.

Industry ResearchOligonucleotide Drug CDMO Services Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Oligonucleotide Drug CDMO Services Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Oligonucleotide Drug CDMO Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oligonucleotide Drug CDMO Services Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Oligonucleotide Drug CDMO Services Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Oligonucleotide Drug CDMO Services market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Oligonucleotide Drug CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Oligonucleotide Drug CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oligonucleotide Drug CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Oligonucleotide Drug CDMO Services market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Oligonucleotide Drug CDMO Services market include Bachem, WuXi TIDES, Ajinomoto Co, Waters, AGC Biologics, Merck KGaA, EUROAPI, CordenPharma and Cytiva, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Oligonucleotide Drug CDMO Services market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Oligonucleotide Drug CDMO Services and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Oligonucleotide Drug CDMO Services revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Oligonucleotide Drug CDMO Services market.

Oligonucleotide Drug CDMO Services Segment by Company

Bachem

WuXi TIDES

Ajinomoto Co

Waters

AGC Biologics

Merck KGaA

EUROAPI

CordenPharma

Cytiva

TriLink BioTechnologies

Medicilon

General Biol

BioSpring

Bio-Synthesis Inc

Aurisco

Suzhou Olipharma Co.,Ltd

Porton

RIBOPharm

Oligonucleotide Drug CDMO Services Segment by Type

API

Preparation

Oligonucleotide Drug CDMO Services Segment by Application

SME Pharmaceutical Company

Large Pharmaceutical Company

Oligonucleotide Drug CDMO Services Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Oligonucleotide Drug CDMO Services status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Oligonucleotide Drug CDMO Services key companies, revenue, market share, and recent developments.

3. To split the Oligonucleotide Drug CDMO Services breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Oligonucleotide Drug CDMO Services market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Oligonucleotide Drug CDMO Services significant trends, drivers, influence factors in global and regions.

6. To analyze Oligonucleotide Drug CDMO Services competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide Drug CDMO Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide Drug CDMO Services and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide Drug CDMO Services.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Oligonucleotide Drug CDMO Services industry.

Chapter 3: Detailed analysis of Oligonucleotide Drug CDMO Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Oligonucleotide Drug CDMO Services in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Oligonucleotide Drug CDMO Services in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Oligonucleotide Drug CDMO Services Industry Trends Table 2. Oligonucleotide Drug CDMO Services Industry Drivers Table 3. Oligonucleotide Drug CDMO Services Industry Opportunities and Challenges Table 4. Oligonucleotide Drug CDMO Services Industry Restraints Table 5. Global Oligonucleotide Drug CDMO Services Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Oligonucleotide Drug CDMO Services Revenue Share by Company (2021-2026) Table 7. Global Oligonucleotide Drug CDMO Services Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Oligonucleotide Drug CDMO Services Key Company Manufacturing Base & Headquarters Table 9. Global Oligonucleotide Drug CDMO Services Company, Product Type & Application Table 10. Global Oligonucleotide Drug CDMO Services Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Oligonucleotide Drug CDMO Services by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of API Table 15. Significant Companies of Preparation Table 16. Global Oligonucleotide Drug CDMO Services Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Oligonucleotide Drug CDMO Services Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Oligonucleotide Drug CDMO Services Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Oligonucleotide Drug CDMO Services Sales Value Share by Type (2021-2026) Table 20. Global Oligonucleotide Drug CDMO Services Sales Value Share by Type (2027-2032) Table 21. Significant Companies of SME Pharmaceutical Company Table 22. Significant Companies of Large Pharmaceutical Company Table 23. Global Oligonucleotide Drug CDMO Services Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Oligonucleotide Drug CDMO Services Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Oligonucleotide Drug CDMO Services Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Oligonucleotide Drug CDMO Services Sales Value Share by Application (2021-2026) Table 27. Global Oligonucleotide Drug CDMO Services Sales Value Share by Application (2027-2032) Table 28. Global Oligonucleotide Drug CDMO Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Oligonucleotide Drug CDMO Services Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Oligonucleotide Drug CDMO Services Sales Value Share by Region (2021-2026) Table 31. Global Oligonucleotide Drug CDMO Services Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Oligonucleotide Drug CDMO Services Sales Value Share by Region (2027-2032) Table 33. Global Oligonucleotide Drug CDMO Services Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Oligonucleotide Drug CDMO Services Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Oligonucleotide Drug CDMO Services Sales Value Market Share by Country (2021-2026) Table 36. Global Oligonucleotide Drug CDMO Services Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Oligonucleotide Drug CDMO Services Sales Value Market Share by Country (2027-2032) Table 38. Bachem Company Information Table 39. Bachem Business Overview Table 40. Bachem Oligonucleotide Drug CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Bachem Oligonucleotide Drug CDMO Services Product Portfolio Table 42. Bachem Recent Development Table 43. WuXi TIDES Company Information Table 44. WuXi TIDES Business Overview Table 45. WuXi TIDES Oligonucleotide Drug CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. WuXi TIDES Oligonucleotide Drug CDMO Services Product Portfolio Table 47. WuXi TIDES Recent Development Table 48. Ajinomoto Co Company Information Table 49. Ajinomoto Co Business Overview Table 50. Ajinomoto Co Oligonucleotide Drug CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Ajinomoto Co Oligonucleotide Drug CDMO Services Product Portfolio Table 52. Ajinomoto Co Recent Development Table 53. Waters Company Information Table 54. Waters Business Overview Table 55. Waters Oligonucleotide Drug CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Waters Oligonucleotide Drug CDMO Services Product Portfolio Table 57. Waters Recent Development Table 58. AGC Biologics Company Information Table 59. AGC Biologics Business Overview Table 60. AGC Biologics Oligonucleotide Drug CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. AGC Biologics Oligonucleotide Drug CDMO Services Product Portfolio Table 62. AGC Biologics Recent Development Table 63. Merck KGaA Company Information Table 64. Merck KGaA Business Overview Table 65. Merck KGaA Oligonucleotide Drug CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Merck KGaA Oligonucleotide Drug CDMO Services Product Portfolio Table 67. Merck KGaA Recent Development Table 68. EUROAPI Company Information Table 69. EUROAPI Business Overview Table 70. EUROAPI Oligonucleotide Drug CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. EUROAPI Oligonucleotide Drug CDMO Services Product Portfolio Table 72. EUROAPI Recent Development Table 73. CordenPharma Company Information Table 74. CordenPharma Business Overview Table 75. CordenPharma Oligonucleotide Drug CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. CordenPharma Oligonucleotide Drug CDMO Services Product Portfolio Table 77. CordenPharma Recent Development Table 78. Cytiva Company Information Table 79. Cytiva Business Overview Table 80. Cytiva Oligonucleotide Drug CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Cytiva Oligonucleotide Drug CDMO Services Product Portfolio Table 82. Cytiva Recent Development Table 83. TriLink BioTechnologies Company Information Table 84. TriLink BioTechnologies Business Overview Table 85. TriLink BioTechnologies Oligonucleotide Drug CDMO Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. TriLink BioTechnologies Oligonucleotide Drug CDMO Services Product Portfolio Table 87. TriLink BioTechnologies Recent Development Table 88. Medicilon Company Information Table 89. Medicilon Business Overview Table 90. Medicilon Oligonucleotide Drug CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Medicilon Oligonucleotide Drug CDMO Services Product Portfolio Table 92. Medicilon Recent Development Table 93. General Biol Company Information Table 94. General Biol Business Overview Table 95. General Biol Oligonucleotide Drug CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. General Biol Oligonucleotide Drug CDMO Services Product Portfolio Table 97. General Biol Recent Development Table 98. BioSpring Company Information Table 99. BioSpring Business Overview Table 100. BioSpring Oligonucleotide Drug CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. BioSpring Oligonucleotide Drug CDMO Services Product Portfolio Table 102. BioSpring Recent Development Table 103. Bio-Synthesis Inc Company Information Table 104. Bio-Synthesis Inc Business Overview Table 105. Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Product Portfolio Table 107. Bio-Synthesis Inc Recent Development Table 108. Aurisco Company Information Table 109. Aurisco Business Overview Table 110. Aurisco Oligonucleotide Drug CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Aurisco Oligonucleotide Drug CDMO Services Product Portfolio Table 112. Aurisco Recent Development Table 113. Suzhou Olipharma Co.,Ltd Company Information Table 114. Suzhou Olipharma Co.,Ltd Business Overview Table 115. Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Product Portfolio Table 117. Suzhou Olipharma Co.,Ltd Recent Development Table 118. Porton Company Information Table 119. Porton Business Overview Table 120. Porton Oligonucleotide Drug CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Porton Oligonucleotide Drug CDMO Services Product Portfolio Table 122. Porton Recent Development Table 123. RIBOPharm Company Information Table 124. RIBOPharm Business Overview Table 125. RIBOPharm Oligonucleotide Drug CDMO Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. RIBOPharm Oligonucleotide Drug CDMO Services Product Portfolio Table 127. RIBOPharm Recent Development Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Oligonucleotide Drug CDMO Services Product Image Figure 2. Global Oligonucleotide Drug CDMO Services Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oligonucleotide Drug CDMO Services Market Size (2021-2032) & (US$ Million) Figure 4. Global Oligonucleotide Drug CDMO Services Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. API Image Figure 8. Preparation Image Figure 9. Global Oligonucleotide Drug CDMO Services Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Oligonucleotide Drug CDMO Services Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Oligonucleotide Drug CDMO Services Sales Value Share by Type (2021-2032) Figure 12. SME Pharmaceutical Company Image Figure 13. Large Pharmaceutical Company Image Figure 14. Global Oligonucleotide Drug CDMO Services Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Oligonucleotide Drug CDMO Services Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Oligonucleotide Drug CDMO Services Sales Value Share by Application (2021-2032) Figure 17. Global Oligonucleotide Drug CDMO Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Oligonucleotide Drug CDMO Services Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Oligonucleotide Drug CDMO Services Sales Value (2021-2032) & (US$ Million) Figure 20. North America Oligonucleotide Drug CDMO Services Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Oligonucleotide Drug CDMO Services Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Oligonucleotide Drug CDMO Services Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Oligonucleotide Drug CDMO Services Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Oligonucleotide Drug CDMO Services Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Oligonucleotide Drug CDMO Services Sales Value (2021-2032) & (US$ Million) Figure 26. South America Oligonucleotide Drug CDMO Services Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Oligonucleotide Drug CDMO Services Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Oligonucleotide Drug CDMO Services Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • API
  • Preparation
Applications
  • SME Pharmaceutical Company
  • Large Pharmaceutical Company
Companies covered
  • Bachem
  • WuXi TIDES
  • Ajinomoto Co
  • Waters
  • AGC Biologics
  • Merck KGaA
  • EUROAPI
  • CordenPharma
  • Cytiva
  • TriLink BioTechnologies
  • Medicilon
  • General Biol
  • BioSpring
  • Bio-Synthesis Inc
  • Aurisco
  • Suzhou Olipharma Co.,Ltd
  • Porton
  • RIBOPharm

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Oligonucleotide Drug CDMO Services Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Oligonucleotide Drug CDMO Services Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Oligonucleotide Drug CDMO Services Market Dynamics
  1. 2.1 Oligonucleotide Drug CDMO Services Industry Trends
  2. 2.2 Oligonucleotide Drug CDMO Services Industry Drivers
  3. 2.3 Oligonucleotide Drug CDMO Services Industry Opportunities and Challenges
  4. 2.4 Oligonucleotide Drug CDMO Services Industry Restraints
3 Oligonucleotide Drug CDMO Services Market by Company
  1. 3.1 Global Oligonucleotide Drug CDMO Services Company Revenue Ranking in 2025
  2. 3.2 Global Oligonucleotide Drug CDMO Services Revenue by Company (2021-2026)
  3. 3.3 Global Oligonucleotide Drug CDMO Services Company Ranking (2024-2026)
  4. 3.4 Global Oligonucleotide Drug CDMO Services Company Manufacturing Base and Headquarters
  5. 3.5 Global Oligonucleotide Drug CDMO Services Company Product Type and Application
  6. 3.6 Global Oligonucleotide Drug CDMO Services Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Oligonucleotide Drug CDMO Services Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Oligonucleotide Drug CDMO Services Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Oligonucleotide Drug CDMO Services Market by Type
  1. 4.1 Oligonucleotide Drug CDMO Services Type Introduction
  2. 4.1.1 API
  3. 4.1.2 Preparation
  4. 4.2 Global Oligonucleotide Drug CDMO Services Sales Value by Type
  5. 4.2.1 Global Oligonucleotide Drug CDMO Services Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Oligonucleotide Drug CDMO Services Sales Value by Type (2021-2032)
  7. 4.2.3 Global Oligonucleotide Drug CDMO Services Sales Value Share by Type (2021-2032)
5 Oligonucleotide Drug CDMO Services Market by Application
  1. 5.1 Oligonucleotide Drug CDMO Services Application Introduction
  2. 5.1.1 SME Pharmaceutical Company
  3. 5.1.2 Large Pharmaceutical Company
  4. 5.2 Global Oligonucleotide Drug CDMO Services Sales Value by Application
  5. 5.2.1 Global Oligonucleotide Drug CDMO Services Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Oligonucleotide Drug CDMO Services Sales Value by Application (2021-2032)
  7. 5.2.3 Global Oligonucleotide Drug CDMO Services Sales Value Share by Application (2021-2032)
6 Oligonucleotide Drug CDMO Services Regional Value Analysis
  1. 6.1 Global Oligonucleotide Drug CDMO Services Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Oligonucleotide Drug CDMO Services Sales Value by Region (2021-2032)
  3. 6.2.1 Global Oligonucleotide Drug CDMO Services Sales Value by Region: 2021-2026
  4. 6.2.2 Global Oligonucleotide Drug CDMO Services Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Oligonucleotide Drug CDMO Services Sales Value (2021-2032)
  7. 6.3.2 North America Oligonucleotide Drug CDMO Services Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Oligonucleotide Drug CDMO Services Sales Value (2021-2032)
  10. 6.4.2 Europe Oligonucleotide Drug CDMO Services Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Oligonucleotide Drug CDMO Services Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Oligonucleotide Drug CDMO Services Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Oligonucleotide Drug CDMO Services Sales Value (2021-2032)
  16. 6.6.2 South America Oligonucleotide Drug CDMO Services Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Oligonucleotide Drug CDMO Services Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Oligonucleotide Drug CDMO Services Sales Value Share by Country, 2025 VS 2032
7 Oligonucleotide Drug CDMO Services Country-level Value Analysis
  1. 7.1 Global Oligonucleotide Drug CDMO Services Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Oligonucleotide Drug CDMO Services Sales Value by Country (2021-2032)
  3. 7.2.1 Global Oligonucleotide Drug CDMO Services Sales Value by Country (2021-2026)
  4. 7.2.2 Global Oligonucleotide Drug CDMO Services Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Oligonucleotide Drug CDMO Services Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Oligonucleotide Drug CDMO Services Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Oligonucleotide Drug CDMO Services Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bachem
  2. 8.1.1 Bachem Company Information
  3. 8.1.2 Bachem Business Overview
  4. 8.1.3 Bachem Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bachem Oligonucleotide Drug CDMO Services Product Portfolio
  6. 8.1.5 Bachem Recent Developments
  7. 8.2 WuXi TIDES
  8. 8.2.1 WuXi TIDES Company Information
  9. 8.2.2 WuXi TIDES Business Overview
  10. 8.2.3 WuXi TIDES Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  11. 8.2.4 WuXi TIDES Oligonucleotide Drug CDMO Services Product Portfolio
  12. 8.2.5 WuXi TIDES Recent Developments
  13. 8.3 Ajinomoto Co
  14. 8.3.1 Ajinomoto Co Company Information
  15. 8.3.2 Ajinomoto Co Business Overview
  16. 8.3.3 Ajinomoto Co Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Ajinomoto Co Oligonucleotide Drug CDMO Services Product Portfolio
  18. 8.3.5 Ajinomoto Co Recent Developments
  19. 8.4 Waters
  20. 8.4.1 Waters Company Information
  21. 8.4.2 Waters Business Overview
  22. 8.4.3 Waters Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Waters Oligonucleotide Drug CDMO Services Product Portfolio
  24. 8.4.5 Waters Recent Developments
  25. 8.5 AGC Biologics
  26. 8.5.1 AGC Biologics Company Information
  27. 8.5.2 AGC Biologics Business Overview
  28. 8.5.3 AGC Biologics Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AGC Biologics Oligonucleotide Drug CDMO Services Product Portfolio
  30. 8.5.5 AGC Biologics Recent Developments
  31. 8.6 Merck KGaA
  32. 8.6.1 Merck KGaA Company Information
  33. 8.6.2 Merck KGaA Business Overview
  34. 8.6.3 Merck KGaA Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck KGaA Oligonucleotide Drug CDMO Services Product Portfolio
  36. 8.6.5 Merck KGaA Recent Developments
  37. 8.7 EUROAPI
  38. 8.7.1 EUROAPI Company Information
  39. 8.7.2 EUROAPI Business Overview
  40. 8.7.3 EUROAPI Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  41. 8.7.4 EUROAPI Oligonucleotide Drug CDMO Services Product Portfolio
  42. 8.7.5 EUROAPI Recent Developments
  43. 8.8 CordenPharma
  44. 8.8.1 CordenPharma Company Information
  45. 8.8.2 CordenPharma Business Overview
  46. 8.8.3 CordenPharma Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  47. 8.8.4 CordenPharma Oligonucleotide Drug CDMO Services Product Portfolio
  48. 8.8.5 CordenPharma Recent Developments
  49. 8.9 Cytiva
  50. 8.9.1 Cytiva Company Information
  51. 8.9.2 Cytiva Business Overview
  52. 8.9.3 Cytiva Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Cytiva Oligonucleotide Drug CDMO Services Product Portfolio
  54. 8.9.5 Cytiva Recent Developments
  55. 8.10 TriLink BioTechnologies
  56. 8.10.1 TriLink BioTechnologies Company Information
  57. 8.10.2 TriLink BioTechnologies Business Overview
  58. 8.10.3 TriLink BioTechnologies Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  59. 8.10.4 TriLink BioTechnologies Oligonucleotide Drug CDMO Services Product Portfolio
  60. 8.10.5 TriLink BioTechnologies Recent Developments
  61. 8.11 Medicilon
  62. 8.11.1 Medicilon Company Information
  63. 8.11.2 Medicilon Business Overview
  64. 8.11.3 Medicilon Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Medicilon Oligonucleotide Drug CDMO Services Product Portfolio
  66. 8.11.5 Medicilon Recent Developments
  67. 8.12 General Biol
  68. 8.12.1 General Biol Company Information
  69. 8.12.2 General Biol Business Overview
  70. 8.12.3 General Biol Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  71. 8.12.4 General Biol Oligonucleotide Drug CDMO Services Product Portfolio
  72. 8.12.5 General Biol Recent Developments
  73. 8.13 BioSpring
  74. 8.13.1 BioSpring Company Information
  75. 8.13.2 BioSpring Business Overview
  76. 8.13.3 BioSpring Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  77. 8.13.4 BioSpring Oligonucleotide Drug CDMO Services Product Portfolio
  78. 8.13.5 BioSpring Recent Developments
  79. 8.14 Bio-Synthesis Inc
  80. 8.14.1 Bio-Synthesis Inc Company Information
  81. 8.14.2 Bio-Synthesis Inc Business Overview
  82. 8.14.3 Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Product Portfolio
  84. 8.14.5 Bio-Synthesis Inc Recent Developments
  85. 8.15 Aurisco
  86. 8.15.1 Aurisco Company Information
  87. 8.15.2 Aurisco Business Overview
  88. 8.15.3 Aurisco Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Aurisco Oligonucleotide Drug CDMO Services Product Portfolio
  90. 8.15.5 Aurisco Recent Developments
  91. 8.16 Suzhou Olipharma Co.,Ltd
  92. 8.16.1 Suzhou Olipharma Co.,Ltd Company Information
  93. 8.16.2 Suzhou Olipharma Co.,Ltd Business Overview
  94. 8.16.3 Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Product Portfolio
  96. 8.16.5 Suzhou Olipharma Co.,Ltd Recent Developments
  97. 8.17 Porton
  98. 8.17.1 Porton Company Information
  99. 8.17.2 Porton Business Overview
  100. 8.17.3 Porton Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Porton Oligonucleotide Drug CDMO Services Product Portfolio
  102. 8.17.5 Porton Recent Developments
  103. 8.18 RIBOPharm
  104. 8.18.1 RIBOPharm Company Information
  105. 8.18.2 RIBOPharm Business Overview
  106. 8.18.3 RIBOPharm Oligonucleotide Drug CDMO Services Revenue and Gross Margin (2021-2026)
  107. 8.18.4 RIBOPharm Oligonucleotide Drug CDMO Services Product Portfolio
  108. 8.18.5 RIBOPharm Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst